ARUP said it is seeing larger volumes of pathology samples, requiring more advanced and efficient workflows.
Multiple variant databases are creating competition among groups that disagree on how to advance the most scientifically robust and sustainable sharing model.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The company said it will use the funds to further develop its DNA search technologies based on the Taxonomer pathogen metagenomics analysis platform.
Co-discoverers of the link between the gene EIF2AK4 and specific types of pulmonary hypertension, Intermountain and ARUP are now collaborating to offer clinical testing.
The DTWG proposal for regulating in vitro clinical tests has made it into draft legislation but it still needs support from key stakeholders in the life sciences field.
Under the partnership, the companies will help drugmakers efficiently implement complementary and companion tests through lab networks.
ARUP's database is one of many options that researchers and oncologists can use to learn about whether alterations in BRCA genes are associated with hereditary breast and ovarian cancer risk.
The group hopes its proposed regulatory framework might strike a compromise between different industry stakeholders.
A new version of its system planned for summer release will feature a score that helps clinicians prioritize variants and an expanded knowledgebase.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.